medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2007, Number 1

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2007; 20 (1)

Treatment of systemic hypertension in patients with asthma and chronic obstructive pulmonary disease

Cobo AC, Fabián San MMG

Language: Spanish
References: 31
Page: 64-70
PDF size: 68.36 Kb.


ABSTRACT

The prevalence of systemic arterial hypertension in patients with pulmonary disease is unknown, but it could be similar to the rest of the population. However, treatment could be different, as beta blockers are generally contraindicated in patients with bronchial asthma and COPD, and the angiotensin-converting enzyme inhibitors can induce cough. This paper reviews the different classes of antihypertensive drugs that can be used in patients with pulmonary diseases, with focus in bronchial asthma and chronic obstructive pulmonary disease.


REFERENCES

  1. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-313.

  2. The National Lung Health Education Program Executive en Committee. Strategies in preserving lung health and preventing COPD and associated diseases. Chest 1998;113(2 Suppl):123-159.

  3. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 1995;10(193 Pt 1):1-260.

  4. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989;262:907-913.

  5. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998;351:1755-1762.

  6. Huiart L, Ernst P, Suissa S. Cardiovascular morbility and mortality in COPD. Chest 2005;128:2640-2646.

  7. Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Woolf SH. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 2003;123:222-243.

  8. Staessen JA, Fagard R, Thijs L, et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Lancet 1997;350:757-764.

  9. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study. Group on Antihypertensive Agents. N Engl J Med 1993;328:914-921.

  10. Higgins M, Keller JB, Wagenknecht LE, et al. Pulmonary function and cardiovascular risk factor relationships in black and in white young men and women. The CARDIA Study. Chest 1991;99:315-322.

  11. Chobanian AV, Bakris GL, Black HR, et al; and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003;289:2560.

  12. Riska H, Sovijarvi AR, Ahonen A, Salorinne Y, Sundberg S, Stenius-Aarniala B. Effects of captopril on blood pressure and respiratory function compared to verapamil in patients with hypertension and asthma. J Cardiovasc Pharmacol 1990;15:57-61.

  13. Lin M, Yang YF, Lee D, Chiang HT. Comparisons of long-term effects of lisinopril vs nifedipine vs conventional therapy in the treatment of mild-to-moderate hypertension in patients with chronic obstructive pulmonary disease. Zhonghua Yi Xue Za Zhi (Taipei) 1996; 57:392-400.

  14. Yilmaz E, Canberk A, Eroglu L. Nifedipine alters serum theophylline levels in asthmatic patients with hypertension. Fundam Clin Pharmacol 1991;5:341-345.

  15. Kantola I, Rauhala E, Erkinjuntti M, Mansury L. Sleep disturbances in hypertension: a double-blind study between isradipine and metoprolol. J Cardiovasc Pharmacol 1991;18 Suppl 3:41-45.

  16. Havelka J, Vetter H, Studer A, et al. Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension. Am J Cardiol 1982;49:1467-1474.

  17. Simon SR, Black HR, Moser M, Berland WE. Cough and ACE inhibitors. Arch Intern Med 1992;152:1698-1700.

  18. Semple PF, Herd GE. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. N Engl J Med 1986;314:61.

  19. Popa V. Captopril-related (and –induced?) asthma. Am Rev Respir Dis 1987;136:999-1000.

  20. Sala H, Abad J, Juanmiguel L, et al. Captopril and bronchial reactivity. Postgrad Med J 1986;62 Suppl 1:76-77.

  21. Bertoli L, Fusco M, LoCicero S, Micallef E, Busnardo I. Influence of ACE inhibition on pulmonary hemodynamics and function in patients in whom beta- blockers are contraindicated. Postgrad Med J 1986;62 Suppl 1:47-51.

  22. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.

  23. The SOLVS Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.

  24. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.

  25. Benz J, Oshrain C, Henry D, Avery C, Chiang YT, Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997;37:101-107.

  26. Chan P, Tomlinson B, Huang TY, Ko JT, Lin TS, Lee YS. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997;37:253-257.

  27. McNeill RS. Effect of a beta-adrenergic-blocking agent, propranolol, on asthmatics. Lancet 1964;13: 1101-1102.

  28. Graft DF, Fowles J, McCoy CE, Lager RA. Detection of beta-blocker use in people with asthma. Ann Allergy 1992;69:449-453.

  29. Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990;4:1145-1149.

  30. Lawrence DS, Sahay JN, Chatterjee SS, Cruickshank JM. Asthma and beta- blockers. Eur J Clin Pharmacol 1982;22:501-509.

  31. Formgren H. The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics. Br J Clin Pharmacol 1976;3:1007-1014.




2020     |     www.medigraphic.com